BioAge Labs, Inc. (BIOA) Stock

BioAge Labs, Inc. (BIOA) is a Healthcare stock trading at $9.48 (as of 2026-08-21), with a market capitalization of $435.33M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

BioAge Labs, Inc. is a clinical-stage biopharmaceutical company that develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets allows users to identify targets based on insights into molecular changes that drive aging. Its product includes azelaprag, an orally available small molecule that is in phase 1 clinical trial for the treatment of obesity; and initiated phase 2 clinical trial of azelaprag in combination with tirzepatide for the treatment of obesity in older adults. It also develops BGE-100, an orally available small molecule brain-penetrant NLRP3 antagonist for the treatment of diseases driven by neuroinflammation. The company was incorporated in 2015 and is based in Richmond, California.

Understand BioAge Labs, Inc.: how it makes money

BioAge Labs is a clinical-stage biopharmaceutical company developing therapies for metabolic diseases, using its platform and human datasets to identify targets based on molecular changes that drive aging, and it makes money (when recognized) through collaboration revenue rather than product sales.

Because reported revenue is collaboration revenue (and the company is still clinical-stage with no product sales provided), the profit model in the near term depends on partnering and collaboration recognition, while trial outcomes mainly affect future partnering and potential commercialization prospects.

Revenue by segment (latest quarter)
Collab	$0.0B

Business quality (Weak): Clinical-stage biopharma with trial-oriented operating readouts and currently no reported revenue beyond collaborations, so fundamentals depend heavily on clinical execution and partnering dynamics.

Bull case

Trial efficacy signals tied to inflammatory biomarkers: The company reports large median reductions from baseline in High-Sensitivity C-Reactive Protein.
Multiple obesity programs in clinical development: Azelaprag is in phase 1 for obesity, and the company has initiated phase 2 of azelaprag in combination with tirzepatide in older adults.

Bear case

No demonstrated commercial revenue in the latest quarter provided: Revenue is reported as 0.0 for the quarter ended 2026-03-31, so the business remains dependent on collaborations and future clinical milestones rather than product sales.
Operational losses are very large: Operating margin is -915.4% for the quarter ended 2026-03-31, indicating heavy cost burn before commercialization.

Valuation — source: SEC EDGAR (first-party)
Price	$9.48
Market Cap	$435.33M
Price / Book	1.16
Price / Sales	43.32
FCF Yield	-33.5%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$8.99M
Net Margin	-896.1%

Financial Health — source: SEC EDGAR
Altman Z-Score	9.55 (safe)

Valuation vs Sector & Industry
Sector P/E (Healthcare)	21.7
Industry P/E (Pharmaceutical Products)	17.2

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	a16z Capital Management, L.L.C. ($56.55M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Kristen Fortney
Employees	62
Country	US
IPO Date	2024-09-26

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.